SCHEMBL20945154

SCHEMBL20945154

O=c1[nH][nH]c(=O)c2c(OCc3ccccc3)cccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.50
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ADORA3 P0DMS8 1/20 0.46
ALDH1A1 P00352 1/20 0.45
SRD5A2 P31213 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.44
EDNRA P25101 1/20 0.44
LTA4H P09960 1/20 0.44
PLA2G2A P14555 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
DCPS Q96C86 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
PLAU P00749 1/20 0.43
PLAT P00750 1/20 0.43
ALPG P10696 1/20 0.43
PTK2B Q14289 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371602 0.74 PARP1 (0.63) MAPTL3MBTL1MAPK1TDP1ADORA3
SCHEMBL4893406 0.73 SRD5A2 (0.56) MAPTL3MBTL1MAPK1TDP1SRD5A2
SCHEMBL26027602 0.73 MEN1 (0.55) MAPTL3MBTL1ALDH1A1LMNA
SCHEMBL31312821 0.73 MEN1 (0.55) MAPTL3MBTL1ALDH1A1LMNA
SCHEMBL4914778 0.73 MAOA (0.61) MAOBMAPTL3MBTL1MAPK1TDP1
SCHEMBL5879271 0.73 ADORA3 (0.53) MAOBMAPTL3MBTL1MAPK1TDP1
SCHEMBL28669651 0.72 F9 (0.49) MAOBMAPTL3MBTL1MAPK1TDP1
SCHEMBL339812 0.71 MAPT (0.71) MAPTL3MBTL1MAPK1TDP1LTA4H
SCHEMBL1681487 0.71 MRGPRX4 (0.55) MAPTL3MBTL1TDP1ALDH1A1SRD5A2
SCHEMBL27629 0.71 MRGPRX4 (0.67) MAPTL3MBTL1MAPK1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415345-B Pyridazinone-based broad-spectrum anti-influenza inhibitors 豪夫迈·罗氏有限公司 2022-01-11 CN disclosed
EP-3478671-B1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS HOFFMANN LA ROCHE (CH) 2020-05-13 EP disclosed
US-10597380-B2 Pyridazinone-based broad spectrum anti-influenza inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-03-24 US disclosed
US-20190127349-A1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127349-A1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS ABCG2, PIR, PRNP MAOB 95/4885MAPT 1263/4885L3MBTL1 4826/4885
US-10597380-B2 Pyridazinone-based broad spectrum anti-influenza inhibitors ABCG2, PIR, PRNP MAOB 95/4885MAPT 1263/4885L3MBTL1 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.